MCID: MRK001
MIFTS: 59

Merkel Cell Carcinoma

Categories: Rare diseases, Cancer diseases, Neuronal diseases, Skin diseases, Endocrine diseases

Aliases & Classifications for Merkel Cell Carcinoma

MalaCards integrated aliases for Merkel Cell Carcinoma:

Name: Merkel Cell Carcinoma 12 49 55 36 28 14 69
Cutaneous Neuroendocrine Carcinoma 49 55
Trabecular Adenocarcinoma 12 69
Carcinoma, Merkel Cell 49
Carcinoma Merkel Cell 51
Trabecular Carcinoma 12
Merkel Cell Cancer 49
Merkle Tumors 49
Mcc 55

Characteristics:

Orphanet epidemiological data:

55
cutaneous neuroendocrine carcinoma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (Europe),1-9/100000 (Australia); Age of onset: Adult; Age of death: elderly;

Classifications:



External Ids:

Disease Ontology 12 DOID:3965
NCIt 46 C4068
SNOMED-CT 64 29792007
Orphanet 55 ORPHA79140
UMLS via Orphanet 70 C0007129
ICD10 via Orphanet 33 C44.3 C44.6 C44.7
KEGG 36 H01555

Summaries for Merkel Cell Carcinoma

NIH Rare Diseases : 49 Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer. It usually develops as a single, painless, bump on sun-exposed skin. The bump may be skin-colored or red-violet, and tends to grow rapidly over weeks to months. It may spread quickly to surrounding tissues, nearby lymph nodes, or more distant parts of the body. Factors associated with developing MCC include increasing age, fair skin, a history of extensive sun exposure, chronic immune suppression, and the Merkel cell polyomavirus. This virus has been detected in about 80% of people with MCC. Treatment may include surgery, radiation therapy, and/or chemotherapy. Treatment options and prognosis depend on the location(s) and size of the cancer, whether it has just been diagnosed or has come back (recurred), and how deeply it has grown into the skin. Last updated: 3/9/2017

MalaCards based summary : Merkel Cell Carcinoma, also known as cutaneous neuroendocrine carcinoma, is related to glomus tumor and spindle cell carcinoma, and has symptoms including merkel cell skin cancer, cutaneous photosensitivity and chronic noninfectious lymphadenopathy. An important gene associated with Merkel Cell Carcinoma is KRT20 (Keratin 20), and among its related pathways/superpathways are NF-kappaB Signaling and Cytoskeletal Signaling. The drugs Antibodies and Antibodies, Monoclonal have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and brain, and related phenotypes are behavior/neurological and nervous system

Wikipedia : 72 Merkel-cell carcinoma (MCC) is a rare and highly aggressive skin cancer, which, in most cases, is caused... more...

Related Diseases for Merkel Cell Carcinoma

Diseases related to Merkel Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 411)
# Related Disease Score Top Affiliating Genes
1 glomus tumor 30.1 ENO2 SYP TP53
2 spindle cell carcinoma 30.0 ENO2 KRT7 MUC1 SYP
3 basal cell carcinoma 30.0 KRT20 KRT7 KRT8 TP53
4 somatostatinoma 29.9 CHGA ENO2 SST
5 paraganglioma 29.7 CHGA ENO2 SST SYP
6 pheochromocytoma 29.6 CHGA ENO2 SST SYP
7 neuroblastoma 29.3 ENO2 KIT NCAM1 SYP TP53
8 small cell neuroendocrine carcinoma 29.1 CHGA ENO2 KIT NCAM1 SYP TP53
9 ewing sarcoma 29.0 CHGA ENO2 KIT NCAM1 SYP TP53
10 small cell carcinoma 28.9 CHGA ENO2 KIT KRT20 KRT7 NCAM1
11 neuroendocrine tumor 28.3 CHGA ENO2 KRT20 KRT7 NCAM1 NKX2-1
12 renal cell carcinoma, nonpapillary 27.7 CD274 ENO2 KIT KRT20 KRT7 KRT8
13 penile cancer 11.1
14 ureter small cell carcinoma 10.6 CHGA SYP
15 acinar cell cystadenocarcinoma 10.6 CHGA SYP
16 peritoneal serous adenocarcinoma 10.6 CHGA SYP
17 malignant sertoli cell tumor 10.6 ENO2 SYP
18 primary hepatic neuroendocrine carcinoma 10.6 CHGA SYP
19 gastrointestinal neuroendocrine tumor 10.6 CHGA SYP
20 mature teratoma of the ovary 10.6 ENO2 KRT20
21 cystic basal cell carcinoma 10.6 KRT20 KRT7
22 intracranial primitive neuroectodermal tumor 10.6 CHGA ENO2
23 seminal vesicle adenocarcinoma 10.5 KRT20 KRT7
24 transverse colon cancer 10.5 KRT20 KRT7
25 mixed type thymoma 10.5 KIT SYP
26 eyelid neoplasm 10.5 KRT20 KRT7
27 malignant syringoma 10.5 KRT20 KRT7
28 krukenberg carcinoma 10.5 KRT20 KRT7
29 mucinous adenofibroma 10.5 KRT7 SYP
30 reticular perineurioma 10.5 KIT MUC1
31 large intestine adenocarcinoma 10.5 KRT20 KRT7
32 linitis plastica 10.5 KRT20 KRT7
33 pilomatrix carcinoma 10.5 ENO2 MUC1
34 intracranial cysts 10.5 ENO2 MUC1
35 ovarian germ cell teratoma 10.5 KRT7 NKX2-1
36 adenoid squamous cell carcinoma 10.5 KRT20 KRT7
37 subependymal glioma 10.5 ENO2 SYP
38 ovarian germ cell cancer 10.5 KRT7 NKX2-1
39 jejunal cancer 10.5 KIT KRT7
40 gastric leiomyosarcoma 10.5 ENO2 KIT
41 prostatic acinar adenocarcinoma 10.5 KIT KRT20
42 bladder papillary transitional cell neoplasm 10.5 KRT20 TP53
43 vulval paget's disease 10.5 KRT20 KRT7
44 lung combined type small cell carcinoma 10.5 NCAM1 SYP
45 urinary tract papillary transitional cell benign neoplasm 10.5 KRT20 TP53
46 bladder adenocarcinoma 10.5 KRT20 KRT7
47 acute thyroiditis 10.5 CHGA ENO2
48 clear cell meningioma 10.5 CHGA MUC1
49 papillary adenoma 10.5 KRT7 NKX2-1
50 microcystic adenoma 10.5 ENO2 MUC1

Graphical network of the top 20 diseases related to Merkel Cell Carcinoma:



Diseases related to Merkel Cell Carcinoma

Symptoms & Phenotypes for Merkel Cell Carcinoma

Human phenotypes related to Merkel Cell Carcinoma:

55 31 (show all 17)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 merkel cell skin cancer 55 31 obligate (100%) Obligate (100%) HP:0030447
2 cutaneous photosensitivity 55 31 frequent (33%) Frequent (79-30%) HP:0000992
3 chronic noninfectious lymphadenopathy 55 31 frequent (33%) Frequent (79-30%) HP:0002730
4 cellular immunodeficiency 55 31 frequent (33%) Frequent (79-30%) HP:0005374
5 regional abnormality of skin 55 31 frequent (33%) Frequent (79-30%) HP:0011356
6 erythematous plaque 55 31 frequent (33%) Frequent (79-30%) HP:0025474
7 erythematous macule 55 31 frequent (33%) Frequent (79-30%) HP:0025475
8 skin nodule 55 31 frequent (33%) Frequent (79-30%) HP:0200036
9 basal cell carcinoma 55 31 occasional (7.5%) Occasional (29-5%) HP:0002671
10 lymphoid leukemia 55 31 occasional (7.5%) Occasional (29-5%) HP:0005526
11 squamous cell carcinoma of the skin 55 31 occasional (7.5%) Occasional (29-5%) HP:0006739
12 multiple myeloma 55 31 occasional (7.5%) Occasional (29-5%) HP:0006775
13 carcinoid tumor 55 31 occasional (7.5%) Occasional (29-5%) HP:0100570
14 abnormal brain fdg positron emission tomography 55 31 very rare (1%) Very rare (<4-1%) HP:0012658
15 brain neoplasm 55 31 very rare (1%) Very rare (<4-1%) HP:0030692
16 neoplasm of the outer ear 55 31 very rare (1%) Very rare (<4-1%) HP:0040095
17 pain 55 Excluded (0%)

MGI Mouse Phenotypes related to Merkel Cell Carcinoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.65 CD274 ENO2 KIT MAP2 NCAM1 NKX2-1
2 nervous system MP:0003631 9.28 ENO2 KIT MAP2 NCAM1 NKX2-1 PAX5

Drugs & Therapeutics for Merkel Cell Carcinoma

Drugs for Merkel Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antibodies Phase 3,Phase 2,Phase 1
2 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
3 Immunoglobulins Phase 3,Phase 2,Phase 1
4
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
5
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
6
Fluorouracil Approved Phase 2,Phase 1 51-21-8 3385
7
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
8 lanreotide Approved Phase 2 108736-35-2
9
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
10
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
11
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
12
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
13
Somatostatin Approved, Investigational Phase 1, Phase 2 38916-34-6, 51110-01-1 53481605
14
nivolumab Approved Phase 2,Phase 1 946414-94-4
15
Pembrolizumab Approved Phase 2,Phase 1 1374853-91-4
16
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
17
Daratumumab Approved Phase 1, Phase 2 945721-28-8
18
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
19
Etoposide Approved Phase 2 33419-42-0 36462
20
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
21
Cisplatin Approved Phase 1, Phase 2 15663-27-1 2767 441203 84093
22
Aldesleukin Approved Phase 1, Phase 2 110942-02-4, 85898-30-2
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
24
leucovorin Approved, Nutraceutical Phase 2,Phase 1 58-05-9 143 6006
25
Glutamic Acid Approved, Nutraceutical Phase 1, Phase 2 56-86-0 33032
26
Camptothecin Experimental Phase 2 7689-03-4
27
Tremelimumab Investigational Phase 1, Phase 2 745013-59-6
28 Albumin-Bound Paclitaxel Phase 2,Phase 1
29 Analgesics Phase 2,Phase 1
30 Analgesics, Non-Narcotic Phase 2,Phase 1
31 Antimitotic Agents Phase 2,Phase 1
32 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
33 Interleukin-2 Phase 2,Phase 1
34 Peripheral Nervous System Agents Phase 2,Phase 1
35 Adjuvants, Immunologic Phase 2
36 Angiogenesis Inhibitors Phase 2,Phase 1
37 Angiogenesis Modulating Agents Phase 2,Phase 1
38 Interleukin-12 Phase 2
39 Vaccines Phase 2,Phase 1
40 Alkylating Agents Phase 2,Phase 1
41 Antimetabolites Phase 2,Phase 1
42 Antimetabolites, Antineoplastic Phase 2,Phase 1
43 Antirheumatic Agents Phase 2,Phase 1
44 Dermatologic Agents Phase 2
45 Folic Acid Antagonists Phase 2
46 Immunosuppressive Agents Phase 2,Phase 1
47 Nucleic Acid Synthesis Inhibitors Phase 2
48 Vitamin B Complex Phase 2
49 Imatinib Mesylate Phase 2 123596
50 Protein Kinase Inhibitors Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 58)

# Name Status NCT ID Phase Drugs
1 Adjuvant Avelumab in Merkel Cell Cancer Recruiting NCT03271372 Phase 3 Avelumab
2 F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma Unknown status NCT02054884 Phase 2 Arm A: F16IL2 in combination with paclitaxel;Arm B: Paclitaxel
3 IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer Completed NCT01440816 Phase 2
4 S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer Completed NCT00003549 Phase 2 CMF regimen;cyclophosphamide;fluorouracil;methotrexate
5 Oblimersen in Treating Patients With Merkel Cell Carcinoma Completed NCT00079131 Phase 2
6 S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer Completed NCT00068783 Phase 2 imatinib mesylate
7 Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues Completed NCT02351128 Phase 2 Lanreotide
8 Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors Completed NCT00004922 Phase 2 irinotecan hydrochloride
9 Capecitabine and Temozolomide for Neuroendocrine Cancers Completed NCT00869050 Phase 2 Capecitabine;Temozolomide
10 Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies Versus Observation Recruiting NCT02196961 Phase 2 Ipilimumab;Nivolumab
11 MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma Recruiting NCT02514824 Phase 1, Phase 2 MLN0128
12 Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma Recruiting NCT02584829 Phase 1, Phase 2 Avelumab
13 A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors Recruiting NCT02819843 Phase 2 TALIMOGENE LAHERPAREPVEC (TVEC)
14 Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma Recruiting NCT03071406 Phase 2 Nivolumab;Ipilimumab
15 Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer Recruiting NCT03304639 Phase 2
16 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting NCT02978625 Phase 2
17 Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma Recruiting NCT03322384 Phase 1, Phase 2 epacadostat;SD-101
18 Pfizer Immunotherapy Combinations for Acute Myeloid Leukemia (AML) Multi-Arm Study 1 Recruiting NCT03390296 Phase 2 PF-04518600;Avelumab;Azacitidine;Utomilumab;Gemtuzumab Ozogamicin;Glasdegib
19 An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors Recruiting NCT02488759 Phase 1, Phase 2 Nivolumab;Ipilimumab;BMS-986016;Daratumumab
20 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Recruiting NCT02936323 Phase 1, Phase 2 PEN-221
21 A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Recruiting NCT02643303 Phase 1, Phase 2 Durvalumab;Tremelimumab;Poly ICLC
22 A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies Recruiting NCT03241173 Phase 1, Phase 2 INCAGN01949;Nivolumab;Ipilimumab;INCAGN01949
23 Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies Recruiting NCT03126110 Phase 1, Phase 2 INCAGN01876;Nivolumab;Ipilimumab
24 INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies Recruiting NCT03277352 Phase 1, Phase 2 INCAGN01876;Epacadostat;Pembrolizumab
25 Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma Active, not recruiting NCT02036476 Phase 2 Cabozantinib
26 QUILT-3.009: Study of aNK Infusions in Combination With ALT-803 in Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC) Active, not recruiting NCT02465957 Phase 2
27 Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200) Active, not recruiting NCT02155647 Phase 2 Avelumab
28 Merkel Positron Emission Tomography (PET) Protocol Active, not recruiting NCT01013779 Phase 2 Carboplatin;Etoposide
29 Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer Active, not recruiting NCT02267603 Phase 2
30 Study of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin's Lymphoma Active, not recruiting NCT02501473 Phase 1, Phase 2 G100;Pembrolizumab
31 Atezolizumab and Bevacizumab in Rare Solid Tumors Active, not recruiting NCT03074513 Phase 2 Atezolizumab;Bevacizumab
32 QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy Not yet recruiting NCT03167164 Phase 1, Phase 2 Capecitabine;Cisplatin;Cyclophosphamide;5-fluorouracil;Leucovorin;nab-Paclitaxel;omega-3-acid ethyl esters
33 A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies Not yet recruiting NCT03435640 Phase 1, Phase 2 NKTR-262;NKTR-214;nivolumab
34 Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma Terminated NCT01758458 Phase 1, Phase 2
35 Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma Withdrawn NCT01913691 Phase 2 Ipilimumab
36 Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy Withdrawn NCT00003514 Phase 2 antineoplaston A10;antineoplaston AS2-1
37 A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel C Completed NCT01652547 Phase 1 Pasireotide sub-cutaneous formulation;Pasireotide lon acting release formulation
38 BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00346385 Phase 1 BB-10901
39 Endoscopic Treatment of Inoperable Colorectal Cancer With the EndoVe System Completed NCT01172860 Phase 1
40 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
41 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
42 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
43 89Zr-Df-IAB22M2C PET/CT in Patients With Selected, Metastatic Solid Malignancies or Hodgkin's Lymphoma Recruiting NCT03107663 Phase 1 89Zr-Df-IAB22M2C Infusion
44 Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides Recruiting NCT02890368 Phase 1 TTI-621 Monotherapy;TTI-621 + PD-1/PD-L1 Inhibitor;TTI-621 + pegylated interferon-α2a
45 Phase 1 Study of CK-301 as a Single Agent in Subjects With Advanced Cancers Recruiting NCT03212404 Phase 1 CK-301
46 A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting NCT03071757 Phase 1 ABBV-368;Nivolumab
47 A Study of ABBV-181 in Participants With Advanced Solid Tumors Recruiting NCT03000257 Phase 1 Rovalpituzumab Tesirine;ABBV-181
48 A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma Active, not recruiting NCT02035657 Phase 1
49 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
50 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib

Search NIH Clinical Center for Merkel Cell Carcinoma

Genetic Tests for Merkel Cell Carcinoma

Genetic tests related to Merkel Cell Carcinoma:

# Genetic test Affiliating Genes
1 Merkel Cell Carcinoma 28

Anatomical Context for Merkel Cell Carcinoma

MalaCards organs/tissues related to Merkel Cell Carcinoma:

38
Skin, Lymph Node, Brain, Lung, T Cells, Pancreas, Thyroid

Publications for Merkel Cell Carcinoma

Articles related to Merkel Cell Carcinoma:

(show top 50) (show all 807)
# Title Authors Year
1
Radiation Therapy Rather Than Surgery for Merkel Cell Carcinoma: The Advantages of Radiation Therapy. ( 29254767 )
2018
2
Adjuvant radiation therapy improves patient survival in early-stage merkel cell carcinoma: A 15-year single-institution study. ( 29314048 )
2018
3
A Monoclonal Antibody to SV40 Large T Antigen (PAb416) Does Not Label Merkel Cell Carcinoma. ( 29430700 )
2018
4
Outcome of Combined Treatment of Surgery and Adjuvant Radio-therapy in Merkel Cell Carcinoma. ( 29379978 )
2018
5
The Touchy Topic of the Touch Cell: A Case of Merkel Cell Carcinoma. ( 29254766 )
2018
6
Demographics and Outcomes of Stage I-II Merkel Cell Carcinoma Treated with Mohs Micrographic Surgery Compared with Wide Local Excision in the National Cancer Data Base. ( 29408552 )
2018
7
New and emerging treatments for metastatic Merkel Cell Carcinoma. ( 29332376 )
2018
8
Insulinoma-associated 1: A novel nuclear marker in Merkel cell carcinoma (cutaneous neuroendocrine carcinoma). ( 29148079 )
2018
9
Merkel Cell Carcinoma of the Cheek. ( 29419589 )
2018
10
Merkel Cell Carcinoma in a Steer. ( 29422311 )
2018
11
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after a8Y1A year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. ( 29347993 )
2018
12
Merkel cell carcinoma in France: A registries-based, comprehensive epidemiological survey. ( 29341266 )
2018
13
Primary Radiation Therapy for Merkel Cell Carcinoma. ( 29254768 )
2018
14
Retrospective study on the correlation between 18-fluorodeoxyglucose uptake in positron emission tomography-computer tomography and tumour volume, cytological activity as assessed with Ki-67 and GLUT-1 staining in 10 cases of Merkel cell carcinoma. ( 29377285 )
2018
15
Cabozantinib in Patients with Advanced Merkel Cell Carcinoma. ( 29445030 )
2018
16
Are there multiple cells of origin of Merkel cell carcinoma? ( 29321666 )
2018
17
Prospective analysis of the utility of 18-FDG PET in Merkel cell carcinoma of the skin: A Trans Tasman Radiation Oncology Group Study, TROG 09:03. ( 29405630 )
2018
18
Somatostatin receptor type 2 expression in Merkel cell carcinoma as a prognostic factor. ( 29265481 )
2017
19
Phospho-STAT5B Expression Is a Prognostic Marker for Merkel Cell Carcinoma. ( 28476799 )
2017
20
The diagnostic utility of Merkel cell polyomavirus immunohistochemistry in a fine needle aspirate of metastatic Merkel cell carcinoma of unknown primary to the pancreas. ( 28802095 )
2017
21
Merkel Cell Carcinoma of the Head and Neck: Recommendations for Diagnostics and Treatment. ( 28762116 )
2017
22
Eyelid Merkel cell carcinoma in a patient treated with golimumab. ( 28841334 )
2017
23
Merkel cell carcinoma: Do Australians have a more aggressive variant and a worse outcome? ( 28804895 )
2017
24
MGMT promoter methylation status in Merkel cell carcinoma: in vitro versus invivo. ( 28405827 )
2017
25
Coincident Metastatic Melanoma and Merkel Cell Carcinoma with Complete Remission on Treatment with Pembrolizumab. ( 28761962 )
2017
26
Efficacy of isolated limb perfusion (ILP) in patients with Merkel cell carcinoma (MCC): A multicenter experience. ( 28802661 )
2017
27
History of chronic inflammatory disorders increases the risk of Merkel cell carcinoma, but does not correlate with Merkel cell polyomavirus infection. ( 27978533 )
2017
28
Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients. ( 28950303 )
2017
29
Aberrant expression of ALK and EZH2 in Merkel cell carcinoma. ( 28359267 )
2017
30
A thoracic vertebral localization of a metastasized cutaneous Merkel cell carcinoma: Case report and review of literature. ( 28868202 )
2017
31
Merkel Cell Carcinoma. ( 28920480 )
2017
32
Merkel Cell Carcinoma with Distant Metastasis to the Clivus Causing Symptoms Mimicking Tolosa-Hunt Syndrome: A Case Report and Literature Review. ( 28868044 )
2017
33
Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma. ( 29273043 )
2017
34
Update on Merkel Cell Carcinoma. ( 28802497 )
2017
35
Merkel cell carcinoma cardiac metastasis causing cardiac tamponade. ( 28951515 )
2017
36
Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. ( 27984768 )
2017
37
Association of expression of the hedgehog signal with Merkel cell polyomavirus infection and prognosis of Merkel cell carcinoma. ( 28551328 )
2017
38
A population-based cohort study of the influence of socioeconomic factors and race on survival in Merkel cell carcinoma. ( 27986144 )
2017
39
Avelumab for the treatment of metastatic Merkel cell carcinoma. ( 28837181 )
2017
40
Increased expression of EZH2 in Merkel cell carcinoma is associated with disease progression and poorer prognosis. ( 28739498 )
2017
41
Subacute Cerebellar Degeneration due to a Paraneoplastic Phenomenon Associated with Metastatic Merkel Cell Carcinoma: A Case Report. ( 28878663 )
2017
42
Advances in Merkel cell carcinoma from a pathologist's perspective. ( 28844339 )
2017
43
Sentinel lymph node biopsy in periocular merkel cell carcinoma: a case report. ( 28931417 )
2017
44
Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy. ( 28916903 )
2017
45
Merkel Cell Polyomavirus Exhibits Dominant Control of the Tumor Genome and Transcriptome in Virus-Associated Merkel Cell Carcinoma. ( 28049147 )
2017
46
Merkel cell polyomavirus and Merkel cell carcinoma. ( 28893943 )
2017
47
Skin ultrasound features of Merkel cell carcinoma. ( 28045198 )
2017
48
Tropomyosin Receptor Kinase A Expression on Merkel Cell Carcinoma Cells. ( 28793172 )
2017
49
Expression of Merkelcell polyomavirus (MCPyV) large T-antigen in Merkel cell carcinoma lymph node metastases predicts poor outcome. ( 28763479 )
2017
50
Presence of the Merkel cell polyomavirus in Merkel cell carcinoma combined with squamous cell carcinoma in a patient with chronic arsenism. ( 27774637 )
2016

Variations for Merkel Cell Carcinoma

Cosmic variations for Merkel Cell Carcinoma:

9 (show all 15)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM11491 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.743G>C p.R248P 19
2 COSM10656 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.742C>T p.R248W 19
3 COSM10660 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.818G>A p.R273H 19
4 COSM1735722 RB1 skin,NS,carcinoma,Merkel cell carcinoma c.298G>A p.G100R 19
5 COSM1735721 RB1 skin,NS,carcinoma,Merkel cell carcinoma c.297G>A p.W99* 19
6 COSM214151 RB1 skin,NS,carcinoma,Merkel cell carcinoma c.585G>A p.W195* 19
7 COSM1731707 RB1 skin,NS,carcinoma,Merkel cell carcinoma c.1789C>T p.Q597* 19
8 COSM5316 PTEN skin,NS,carcinoma,Merkel cell carcinoma c.439A>T p.K147* 19
9 COSM766 PIK3CA skin,NS,carcinoma,Merkel cell carcinoma c.1636C>A p.Q546K 19
10 COSM27133 PIK3CA skin,NS,carcinoma,Merkel cell carcinoma c.1633G>C p.E545Q 19
11 COSM760 PIK3CA skin,NS,carcinoma,Merkel cell carcinoma c.1624G>A p.E542K 19
12 COSM776 PIK3CA skin,NS,carcinoma,Merkel cell carcinoma c.3140A>T p.H1047L 19
13 COSM249774 PIK3CA skin,NS,carcinoma,Merkel cell carcinoma c.56G>A p.R19K 19
14 COSM29052 PTCH1 skin,back,carcinoma,NS c.724C>T p.Q242* 16
15 COSM763 PIK3CA skin,back,carcinoma,NS c.1633G>A p.E545K 16

Copy number variations for Merkel Cell Carcinoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 32219 1 34600000 44100000 Amplification MYCL1 Merkel cell carcinoma
2 77110 13 40100000 73300000 Deletion Merkel cell carcinoma
3 200959 5 63200000 102800000 Deletion Merkel cell carcinoma

Expression for Merkel Cell Carcinoma

Search GEO for disease gene expression data for Merkel Cell Carcinoma.

Pathways for Merkel Cell Carcinoma

Pathways related to Merkel Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.07 CD274 KIT NCAM1 PAX5
2 11.95 KRT20 KRT7 KRT8 MUC1
3 11.55 ENO2 MAP2 NCAM1 NKX2-1 SYP
4 11.03 MAP2 NCAM1 SYP

GO Terms for Merkel Cell Carcinoma

Biological processes related to Merkel Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cornification GO:0070268 9.43 KRT20 KRT7 KRT8
2 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.32 MUC1 TP53
3 mast cell degranulation GO:0043303 9.16 CHGA KIT
4 mast cell chemotaxis GO:0002551 8.96 CHGA KIT
5 mast cell cytokine production GO:0032762 8.62 CHGA KIT

Sources for Merkel Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....